Provided by Tiger Trade Technology Pte. Ltd.

ResMed

219.58
-0.3700-0.17%
Volume:923.14K
Turnover:202.76M
Market Cap:31.67B
PE:21.05
High:221.25
Open:217.93
Low:215.80
Close:219.95
52wk High:284.87
52wk Low:180.27
Shares:144.25M
Float Shares:143.49M
Volume Ratio:0.69
T/O Rate:0.64%
Dividend:2.40
Dividend Rate:1.09%
EPS(TTM):10.43
EPS(LYR):10.43
ROE:24.27%
ROA:14.00%
PB:4.81
PE(LYR):21.05

Loading ...

Resmed CEO Michael Farrell Sells 4,991 Shares for $1.09 Million

Reuters
·
Jul 09

Jarden Adjusts ResMed's Price Target to AU$40.20 from AU$42.70, Keeps at Overweight

MT Newswires Live
·
Jul 09

ResMed's Sale of MatrixCare Shows Willingness to Recycle Capital From Rationalizing Underperforming Units, Jarden Says

MT Newswires Live
·
Jul 09

Resmed Willing to Cut Underperforming Assets

Dow Jones
·
Jul 09

Resmed's $490M Sale Looks Strategically Sound

Dow Jones
·
Jul 09

ResMed: MatrixCare Divestiture Sharpens SaaS Growth Outlook, Supports Attractive Valuation and Reiterated Buy Rating

TIPRANKS
·
Jul 09

ResMed's $490 Million Sale of MatrixCare Not Material to Outlook, RBC Says

MT Newswires Live
·
Jul 08

Analysts Offer Insights on Healthcare Companies: Resmed (RMD) and Prime Medicine, Inc. (PRME)

TIPRANKS
·
Jul 08

Movement Alert|ResMed Falls 5.29% in Regular Trading, MatrixCare Divestiture Announcement Coupled with RBC Price Target Cut

Market Focus
·
Jul 08

RBC Capital Cuts ResMed Price Target to $276 From $321, Maintains Outperform Rating

MT Newswires Live
·
Jul 08

Resmed is Maintained at Equal-weight by Wells Fargo

Dow Jones
·
Jul 08

ResMed price target lowered to $225 from $227 at Wells Fargo

TIPRANKS
·
Jul 08

Deals of the Day-mergers and Acquisitions

Reuters
·
Jul 08

Resmed Inc : RBC Cuts Target Price to $276 from $321

THOMSON REUTERS
·
Jul 08

Resmed Bull Sees Divestment Sharpening Strategic Focus

Dow Jones
·
Jul 08

Resmed's Matrixcare Sale May Hint at AI Disruption Risk

Dow Jones
·
Jul 08

Resmed - Deal Valued at $490 Mln All-cash, Expected to Close in Q1 Fy2027 - SEC Filing

THOMSON REUTERS
·
Jul 08

Resmed - Reiterates Q4 Fy2026 Outlook for Net Interest Income and Share Repurchases - SEC Filing

THOMSON REUTERS
·
Jul 08

Resmed - Reiterates Fy2026 Outlook for Non-gaap Gross Margin, Sg&a, R&D, and Non-gaap Tax Rate - SEC Filing

THOMSON REUTERS
·
Jul 08

Resmed Sees 3Q Closing for Matrixcare Divestiture

Dow Jones
·
Jul 08